Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Once a Silicon Valley pioneer in consumer genetic testing, 23andMe is now at the center of a high-stakes legal and financial ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Me will hold a second auction for its DNA data with an opening bid of $305 million from former CEO Anne Wojcicki. Here's all ...

After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a ...

Bankrupt genetic testing company 23andMe is looking to sell its assets — most notably its customers' DNA data — for more than ...

Twenty-eight Oregon seniors have won one of the most prestigious academic awards for high schoolers, the $2,500 National ...

A buyer had actually already been found for 23andme, but a competitor is not giving up: The ex-boss of the company may have ...